EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 13
Issue: 8
Year: 2026

A REVIEW ON PROCESS ANALYTICAL TECHNOLOGY (PAT): APPLICATIONS IN QUALITY ASSURANCE OF PHARMACEUTICAL MANUFACTURING

[1*]Taufik U. Mulla, [2]Sarang D. Kulkarni, [3]Dr. P. N. Sable, [4]Mrs. Sharda S. Kulkarni

Department of Pharmaceutical Quality Assurance, S.S P. Shikshan Sanstha's Siddhi College of Pharmacy, Chikhali, Pune, Maharashtra 411062, India.

***Corresponding Author: Taufik U. Mulla**

Department of Pharmaceutical Quality Assurance, S.S P. Shikshan Sanstha's Siddhi College of Pharmacy, Chikhali, Pune, Maharashtra 411062, India.

DOI: https://doi.org/10.5281/zenodo.21702380

How to cite this Article: [1]Taufik U. Mulla, [2]Sarang D. Kulkarni, [3]Dr. P. N. Sable, [4]Mrs. Sharda S. Kulkarni. (2026). A Review on Process Analytical Technology (PAT): Applications in Quality Assurance of Pharmaceutical Manufacturing. European Journal of Biomedical and Pharmaceutical Sciences, 13(8), 54–61.

Article Received on 30/06/2026 **Article Revised on 20/07/2026** **Article Published on 01/08/2026**

ABSTRACT

Conventional pharmaceutical production has largely depended on predefined manufacturing instructions followed by laboratory examination of the finished product. Although this approach can confirm compliance of tested samples, it provides limited information about process behaviour while manufacturing is in progress. Process Analytical Technology (PAT) changes this perspective by introducing timely measurements, multivariate analysis, and process-control strategies directly into production. The concept, formally encouraged through the U.S. FDA PAT framework, complements the Quality by Design principles described in ICH Q8(R2), quality risk management in ICH Q9, and the pharmaceutical quality system in ICH Q10. This review discusses the scientific basis, regulatory framework, principal tools, and quality-assurance applications of PAT. Particular attention is given to near-infrared and Raman spectroscopy, chemometrics, real-time process monitoring, and real-time release testing. Applications during material identification, blending, granulation, drying, compression, coating, continuous manufacturing, and bioprocessing are reviewed. Practical benefits and implementation difficulties are also considered, together with emerging developments involving machine learning, data fusion, digital twins, and Industry 4.0. Overall, PAT supports a preventive and knowledge-based quality system in which manufacturing quality is monitored and controlled during processing rather than assessed only after batch completion.

KEYWORDS: Process Analytical Technology; Quality Assurance; Quality by Design; Near-Infrared Spectroscopy; Raman Spectroscopy; Chemometrics; Real-Time Release Testing; Continuous Manufacturing.

1. INTRODUCTION

Pharmaceutical quality control was traditionally centered on compliance with a fixed manufacturing formula and subsequent testing of selected finished-product samples. In such a system, manufacturing is completed before many quality problems become visible. A failed test can identify a non-conforming batch, but it may not clearly explain when the deviation began or which process variable was responsible. In addition, conclusions based on a limited number of samples may not fully describe variation throughout an entire batch.

The Process Analytical Technology initiative was developed to promote a more scientific understanding of pharmaceutical processes. In its 2004 guidance, the U.S. Food and Drug Administration described PAT as a framework for designing, analyzing, and controlling manufacturing through timely measurement of important quality and performance characteristics.[1] The objective is not simply to install analytical instruments on a production line. Instead, PAT combines process knowledge, suitable sensors, data analysis, risk assessment, and control strategies so that variability can be recognized and managed while production is occurring.

PAT is strongly associated with Quality by Design (QbD). ICH Q8(R2) introduces concepts including the Quality Target Product Profile (QTPP), critical quality attributes (CQAs), critical process parameters (CPPs),

and design space.[3] ICH Q9 provides a structured basis for identifying and prioritizing risks,[4] whereas ICH Q10 describes a lifecycle pharmaceutical quality system that uses knowledge management and continual improvement.[5] Within this integrated framework, PAT supplies real-time information about the process and may allow corrective action before a deviation develops into product failure.

Modern PAT applications commonly use spectroscopic instruments such as near-infrared (NIR) and Raman systems. The complex signals obtained from these instruments are interpreted using chemometrics techniques, including principal component analysis (PCA) and partial least squares (PLS) regression[9,10]. When validated measurements are linked with automated process control, manufacturing parameters can be adjusted according to the current state of the process. In advanced applications, reliable in-process information can contribute to real-time release testing (RTRT). This review examines the principles, regulatory basis, technologies, pharmaceutical applications, advantages, limitations, and future development of PAT in quality assurance.

2. Principles of Process Analytical Technology



Figure 1: Integration of PAT with QbD, quality risk management, and the pharmaceutical quality system.

2.1 Meaning and Scope of PAT

PAT should be understood as an integrated system rather than a single analytical technique. The FDA framework includes chemical, physical, microbiological, mathematical, and risk-based tools capable of providing real-time or near-real-time information about materials and manufacturing processes.[1] A process analyzer alone does not automatically provide meaningful quality information. The measurement must be related to a relevant material property, CQA, or process condition through an appropriately developed and validated analytical model.

Many PAT measurements are multivariate. For example, an NIR spectrum contains information across numerous wavelengths, and the response may be influenced by concentration, moisture, particle size, and physical state. Chemometrics approaches are therefore used to extract useful patterns from complex datasets. PCA is frequently used to explore variation and identify clustering or unusual observations, whereas PLS regression can relate spectral data to a quantitative reference value such as drug concentration or moisture content.[6,10]

2.2 PAT within Quality by Design

QbD provides the broader development philosophy in which PAT operates. Product development begins by defining the intended quality characteristics in the QTPP. Scientific knowledge and risk assessment are then used to identify CQAs that must be controlled to ensure product performance. Studies of formulation variables and processing conditions help identify CPPs and material attributes that significantly affect those CQAs.[3,7]

A justified design space describes combinations of process conditions and material variables that have been demonstrated to provide acceptable quality. PAT can continuously or periodically assess whether the process remains in the intended operating region. If a monitored response begins to move away from its target, a suitable control strategy may adjust the relevant process parameter. In this manner, PAT converts process understanding into practical monitoring and control.

2.3 Monitoring, Feedback Control, and Real-Time Release

PAT applications can range from observation to automated control. In process monitoring, data are gathered throughout manufacturing and assessed by production or quality personnel to understand process performance and identify any unusual changes. A more advanced system uses feedback control, where a measured process response causes an adjustment after a deviation is detected. Feedforward control uses information about an upstream disturbance to modify a

later operation before the disturbance adversely affects product quality.

The most mature applications may support RTRT. Under this concept, a validated combination of process measurements and controls provides sufficient evidence that specified quality requirements have been met.[7,15,19] RTRT does not mean that testing is simply omitted. It requires a scientifically justified control strategy, reliable analytical models, appropriate validation, and continued verification. In practice, manufacturers may introduce RTRT for selected attributes or manufacturing stages before extending it to a broader release strategy.[19,20]

2.4 Process Understanding and Knowledge Generation

Pharmaceutical operations are influenced by multiple interacting variables. Blend uniformity, for example, may depend on powder flow, particle characteristics, blender loading, rotational speed, and mixing duration. Evaluating only one variable at a time can fail to describe these interactions. Multivariate experimentation and PAT measurements generate a more detailed picture of process behaviour.[7] The resulting information contributes to process knowledge and supports the knowledge-management and continual-improvement expectations of ICH Q10.[5]

3. Regulatory Perspective: FDA and ICH Guidelines

Table 1: Major regulatory guidelines supporting PAT implementation.

Guideline	Issuing body / year	Principal relevance to PAT
PAT Guidance	FDA, 2004	Framework for timely measurement, process understanding, and manufacturing control.
ICH Q8(R2)	ICH, 2009	Pharmaceutical development, CQAs, CPPs, QTPP, and design space.
ICH Q9	ICH, 2005	Risk-based identification, assessment, and control of quality risks.
ICH Q10	ICH, 2008	Lifecycle pharmaceutical quality system, knowledge management, and continual improvement.

The regulatory foundation of PAT is based on a science- and risk-based approach to pharmaceutical development and manufacturing. The FDA PAT guidance published in 2004 encouraged industry to improve process understanding and to use timely measurements for better manufacturing control.[1,2] Importantly, PAT was presented as a voluntary framework intended to facilitate innovation rather than create an additional routine testing requirement.

ICH Q8(R2), Q9, and Q10 provide a complementary regulatory structure. ICH Q8(R2) focuses on pharmaceutical development and explains QTPP, CQAs, design space, and enhanced process understanding.[3] ICH Q9 establishes principles for quality risk management and supports the use of tools such as failure mode and effects analysis to prioritize significant risks.[4] ICH Q10 integrates these activities into the pharmaceutical quality system, extending across the entire product lifecycle, from pharmaceutical development and technology transfer to commercial manufacturing and eventual product discontinuation.[5]

The relationship between these guidelines is particularly important for PAT implementation. Q8 helps determine what product and process characteristics require understanding; Q9 helps decide which risks deserve the greatest attention; and Q10 ensures that process knowledge, change management, corrective and preventive action, and continual improvement are maintained throughout the lifecycle.[3–6] PAT provides measurements that support these activities.

Regulatory flexibility may be possible when a manufacturer demonstrates a high level of process understanding and control. Operation within an approved design space can provide greater manufacturing flexibility under the principles of ICH Q8(R2).[3] Similarly, RTRT may reduce dependence on conventional end-product release tests when in-process measurements reliably predict the relevant quality attributes.[1,19] Such approaches require strong model validation, data integrity, change control, and continued assurance that the process remains in a state of control.[5,20,21]

4. PAT Tools and Technologies



Figure 2: Four major categories of Process Analytical Technology tools.

The FDA framework groups PAT tools into four broad areas: multivariate tools for design and data analysis, process analyzers, process-control tools, and systems for continuous improvement and knowledge management.[1,7] Effective implementation usually combines elements from each group.

4.1 Multivariate Analysis and Chemometrics

Table 2: Representative PAT tools and their pharmaceutical applications.

PAT tool / technique	Measurement basis	Representative pharmaceutical application
NIR spectroscopy	Overtone and combination molecular vibrations	Material identity, blend uniformity, moisture, potency, coating monitoring
Raman spectroscopy	Inelastic scattering of monochromatic light	Polymorphs, low-dose uniformity, bioprocess monitoring
Particle-size analysis	Laser diffraction or focused-beam reflectance	Granulation and crystallization monitoring
UV–Visible spectroscopy	Electronic absorption	Dissolution and reaction monitoring
Electrochemical / physical sensors	pH, oxygen, conductivity, temperature and related variables	Fermentation, cell culture, and general process monitoring

Pharmaceutical process data are often complex because several variables change simultaneously. Chemometric methods convert large analytical datasets into interpretable process information. PCA can reveal major sources of variation and detect unusual samples, while PLS regression is widely applied to quantitative prediction from spectral measurements.[6,10] More recently, data-fusion strategies have been investigated to combine information from different sensors. Such combinations may improve process description, although validation and integration remain challenging in regulated manufacturing.[16]

4.2 Near-Infrared Spectroscopy

NIR spectroscopy is one of the most established PAT techniques. It measures overtone and combination vibrations, particularly those associated with C–H, N–H, and O–H bonds. Measurements are rapid, usually non-destructive, and can be performed at-line, on-line, or in-line. Pharmaceutical uses include material identification, monitoring of blend uniformity, moisture determination, drying endpoint assessment, tablet potency estimation, and evaluation of coating processes.[6,9,10]

4.3 Raman Spectroscopy

Raman spectroscopy measures inelastic scattering produced when monochromatic light interacts with a sample. It provides chemically specific information and is generally less affected by water than NIR spectroscopy. Reported applications include polymorph identification, content-uniformity monitoring, characterization of low-dose formulations, counterfeit detection, and bioprocess monitoring.[9,13] NIR and Raman may also be used as complementary techniques because each responds differently to chemical and physical properties.[11,14]

4.4 Other Process Analyzers and Sensors

PAT is not limited to vibrational spectroscopy. Laser diffraction and focused-beam reflectance measurements can provide particle-size information during granulation or crystallization. UV-visible spectroscopy may be applied to dissolution or reaction monitoring.

Electrochemical and physical sensors can continuously measure pH, dissolved oxygen, conductivity, temperature, pressure, or capacitance. Mass spectrometric and other advanced analytical techniques may also be selected according to process requirements.[1,17]

4.5 Process Control and Knowledge-Management Systems

Once a validated model converts analytical signals into a meaningful quality estimate, the result can be linked to a process-control system. Feedback control corrects the process according to the measured response, while feedforward control compensates for a known upstream change. Model predictive control is particularly relevant to continuous manufacturing because it can consider interactions and delays between several connected unit operations.[15,17,21]

Long-term PAT success also depends on effective data management. Data historians, electronic batch records, laboratory systems, and structured databases can preserve process information for trend analysis, investigations, and model maintenance. These systems help transform PAT data into organizational knowledge and documented evidence of continued control, consistent with ICH Q10.[5] However, integration of data generated by different instruments and legacy systems continues to be a major practical difficulty.[18]

5. Applications of PAT in Pharmaceutical Quality Assurance



Figure 3: Comparison of traditional end-product testing and a PAT-enabled quality-assurance workflow.

PAT can be applied throughout the manufacturing sequence. At raw-material receipt, handheld or at-line NIR and Raman instruments can compare spectra with validated reference libraries to support rapid identification of active ingredients and excipients.[6,9] This approach may reduce the time associated with conventional laboratory identification while improving the speed of material verification.

Powder blending is a widely studied PAT application. Traditional blending often uses a fixed mixing time followed by thief sampling. In-line NIR monitoring can observe spectral changes as the mixture approaches a stable, homogeneous condition and may support a scientifically defined blending endpoint.[9,11] For formulations containing a low proportion of active ingredient, spatially resolved NIR and Raman approaches have been investigated to detect small variations in blends and tablets.[11,14]

During wet granulation, particle-size and moisture information can help determine process progression and endpoint. This is valuable because inadequate granulation may produce poor flow or content variability, whereas excessive granulation may alter downstream processing. PAT tools help manufacturers understand the actual condition of materials during processing rather than simply assuming that a process is complete after a fixed period of time.

Drying is another important application. A fixed drying period may not account for variation in initial moisture, environmental humidity, batch load, or previous processing. In-line NIR measurements can estimate residual moisture and allow the operation to stop when the intended endpoint is achieved.[6,9] This may prevent unnecessary drying and reduce the risk of retaining excessive moisture.

During tablet manufacture, spectroscopic systems positioned in or near the feed frame can monitor formulation composition, while at-line or rapid NIR methods can estimate tablet potency and uniformity.[11,14] In coating operations, NIR measurements can follow changes associated with coating thickness or coating progress. Such monitoring is especially valuable for

modified-release dosage forms, where coating characteristics may influence drug-release behaviour.[6,10]

PAT is particularly important in continuous manufacturing. In a continuous line, material moves rapidly from one unit operation to another, and delayed laboratory results may arrive only after a substantial quantity of material has already progressed downstream. Real-time sensors, material tracking, and automated control allow disturbances to be identified and managed more quickly.[15] A validated network of measurements may also contribute to RTRT for selected quality attributes.[1,7,19,20]

Applications extend beyond solid oral dosage forms. In bioprocessing, Raman and other sensors can monitor variables related to nutrients, metabolites, cell culture, and product formation. These measurements may guide feeding or other process adjustments and support more consistent operation.[9,17] The increasing volume and complexity of bioprocess data have also stimulated interest in machine-learning-based soft sensors and predictive models.[18]

6. Benefits of PAT for Quality Assurance



Figure 4. Simplified PAT feedback loop for real-time process monitoring and adjustment.

The principal quality advantage of PAT is its preventive approach. Instead of waiting for a finished batch to fail a test, manufacturers can observe important process changes while production is underway. Continuous or frequent measurement provides information from a much larger portion of the process than conventional limited sampling and can improve understanding of within-batch variability.[1,7]

PAT may also improve manufacturing efficiency. Earlier recognition of abnormal trends can reduce the quantity of material affected by a deviation and may lower the need for reprocessing or batch rejection. Better endpoint determination can prevent unnecessary processing, while RTRT can shorten the time required for batch disposition when an approved and validated release strategy is available.[16]

From a lifecycle perspective, PAT creates detailed process knowledge that can support investigations, continual improvement, and more informed change management. When combined with QbD and an established design space, this knowledge may provide regulatory and operational flexibility.[1,3,6] Rapid identity testing can also strengthen material-control systems and reduce the risk of using an incorrect raw material.[1,9]

7. CHALLENGES AND LIMITATIONS

Despite its advantages, PAT implementation can be technically demanding. Chemometric models must be developed using representative calibration samples that cover the expected sources of manufacturing variability. A model constructed from a narrow dataset may perform poorly when raw-material properties, environmental conditions, or process settings move beyond the calibration range. NIR spectra may be influenced by physical factors such as particle size and density, while Raman measurements can be affected by fluorescence.[6,10,13]

Model lifecycle management is another major concern. A calibration model should not be treated as a permanent, one-time product. Changes in suppliers, equipment, analytical probes, formulations, or manufacturing conditions may alter model performance. Procedures are therefore required for monitoring model suitability, managing changes, and performing revalidation when justified.[1,5]

PAT also produces large quantities of data in different formats. Information may be distributed across instrument software, process historians, laboratory information systems, and electronic batch records. Combining these sources into a reliable and

contextualized dataset is difficult, particularly in older manufacturing facilities. Data-fusion approaches can add further validation and governance requirements.[16,18]

Successful adoption requires cooperation among analytical scientists, formulation and process specialists, engineers, quality assurance personnel, information-technology teams, and regulatory professionals. Organizational separation between these groups can delay implementation.[5] Some companies may use PAT for process monitoring but avoid full RTRT because of uncertainty regarding model validation, regulatory documentation, or lifecycle maintenance.[1,6,20]

Cost is also relevant. Process analyzers, probes, software, automation interfaces, and specialized expertise may require considerable initial investment. The financial benefits are often distributed across the product lifecycle through fewer failures, faster release, and improved process understanding. Consequently, the return on investment may be less obvious during the early implementation stage, particularly for small manufacturers or older products.[16]

8. Future Perspectives: AI, Machine Learning, Digital Twins, and Industry 4.0

Conventional Chemometric methods such as PCA and PLS remain central to PAT; however, interest in machine learning is increasing. Machine learning can be particularly helpful when process parameters and quality attributes are linked through complex, nonlinear relationships or when data are obtained from multiple sources and analytical systems. These approaches can be used in several areas, including soft sensor development, early identification of process deviations, prediction of critical quality attributes (CQAs), and interpretation of complex data generated during biopharmaceutical processes.[18] Nevertheless, pharmaceutical datasets may be relatively small, proprietary, and highly regulated, which can complicate model development and independent evaluation.

Data fusion is another developing field. Combining spectral, physical, environmental, and equipment data may provide a more complete description of process state than a single sensor. Pharmaceutical adoption remains limited compared with some other process industries because of differences in data structure, instrument integration, and validation expectations.[16]

Digital twins represent a further extension of process modelling. A digital twin is a virtual representation of a physical system that is updated using data from the real process. In more advanced applications, virtual models can help researchers understand how a process behaves, anticipate changes in process conditions, and assess different control strategies before they are applied to the actual manufacturing process. When connected with PAT data streams, digital twins may support deviation prediction, process optimization, and predictive maintenance.[18,22]

The expansion of continuous manufacturing and Industry 4.0 is likely to increase the importance of PAT. Connected sensors, automated data transfer, advanced analytics, and integrated control systems can create manufacturing environments in which quality information is continuously generated and acted upon.[15,18] However, newer computational methods do not remove the need for sound pharmaceutical science. Reliable measurements, representative data, validated models, data integrity, controlled model changes, and an effective pharmaceutical quality system remain essential.

9. CONCLUSION

Process Analytical Technology has contributed to a major change in the philosophy of pharmaceutical quality assurance. The emphasis is shifting from confirming quality only after manufacturing toward understanding, monitoring, and controlling the factors that create quality during production. The FDA PAT framework and the principles of ICH Q8(R2), Q9, and Q10 provide a scientific and regulatory basis for this approach.[1,3–5]

By combining process analyzers, chemometrics, risk-based development, and process-control systems, PAT can provide timely information about CQAs and the variables that influence them. NIR and Raman spectroscopy are prominent examples, but particle-size analyzers, electrochemical sensors, UV-visible methods, and other technologies also contribute according to the manufacturing process. Applications across blending, granulation, drying, tableting, coating, continuous manufacturing, and bioprocessing demonstrate the broad relevance of PAT.

Important barriers remain, particularly calibration-model development and maintenance, data integration, investment cost, cross-functional collaboration, and the validation requirements associated with RTRT.[16,18] Future integration with machine learning, data fusion, and digital twins may extend predictive and automated quality control. These developments will be most valuable when built on the fundamental PAT principle that consistent pharmaceutical quality is achieved through scientific process understanding and effective real-time control.

REFERENCES

1. U.S. Food and Drug Administration. (2004). *PAT framework for advancing pharmaceutical development, production, and quality management*. U.S. Department of Health and Human Services.
2. Federal Register. (2004). *Availability of industry guidance on Process Analytical Technology for innovative pharmaceutical development, production, and quality assurance*. 69 FR 59261.

3. International Council for Harmonization. (2009). *ICH Q8(R2): Guidance on pharmaceutical product and process development*. ICH.
4. International Council for Harmonization. (2005). *ICH Q9: Principles and practices of quality risk management*. ICH.
5. International Council for Harmonization. (2008). *ICH Q10: Framework for pharmaceutical quality systems*. ICH.
6. European Medicines Agency. (2025). *Questions and answers concerning ICH Q8, Q9, and Q10 (Revision 5)* [Scientific guideline]. EMA.
7. Yu, L. X. (2008). Quality by design in pharmaceuticals: Understanding, developing, and controlling products and manufacturing processes. *Pharmaceutical Research, 25*(4): 781–791.
8. De Beer, T., Burggraeve, A., Fonteyne, M., Saerens, L., Remon, J. P., & Vervaet, C. (2011). Application of near-infrared and Raman spectroscopic methods for in-process observation of pharmaceutical manufacturing. *International Journal of Pharmaceutics, 417*(1–2): 32–47.
9. Roggo, Y., Chalus, P., Maurer, L., Lema-Martinez, C., Edmond, A., & Jent, N. (2007). Application and evaluation of near-infrared spectroscopy with Chemometric methods in pharmaceutical analysis. *Journal of Pharmaceutical and Biomedical Analysis, 44*(3): 683–700.
10. Chavez, P. F., et al. (2015). Design-space-based optimization of a pharmaceutical tablet formulation using vibrational spectroscopy as a PAT technique. *International Journal of Pharmaceutics, 486*(1–2): 13–20.
11. Ortega-Zúñiga, C. A., et al. (2025). Real-time identification of minor variations in powder mixtures and low-dose tablets using Raman and spatially resolved near-infrared spectroscopy. *International Journal of Pharmaceutics, 670*: 125165.
12. Simon, L. L., et al. (2015). Evaluation of emerging developments and recent trends in process analytical technology: A collaborative review. *Organic Process Research & Development, 19*(1): 3–62.
13. Esmonde-White, K. A., Cuellar, M., Uerpmann, C., Lenain, B., & Lewis, I. R. (2017). Use of Raman spectroscopy as a PAT approach in pharmaceutical production and bioprocess monitoring. *Analytical and Bioanalytical Chemistry, 409*(3): 637–649.
14. Casian, T., et al. (2017). Development and comparative validation of rapid NIR and Raman methods for evaluating amlodipine–valsartan tablets. *Talanta, 167*: 333–343.
15. Lee, S. L., et al. (2015). Advancement of pharmaceutical production from traditional batch processing towards continuous manufacturing. *Journal of Pharmaceutical Innovation, 10*(3): 191–199.
16. Casian, T., Nagy, B., Kovács, B., Galata, D. L., Hirsch, E., & Farkas, A. (2022). Opportunities and practical difficulties associated with data fusion in process analytical technology: A review. *Molecules, 27*(15): 4846.
17. Gerzon, G., Sheng, Y., & Kirkitadze, M. (2022). Recent progress in process analytical technologies for bioprocess integration and future applications. *Journal of Pharmaceutical and Biomedical Analysis, 207*: 114379.
18. Khuat, T. T., Bassett, R., Otte, E., Grevis-James, A., & Gabrys, B. (2023). Current applications, limitations, and future potential of machine learning in biopharmaceutical process development and manufacturing. *arXiv*, 2310.09991.
19. Markl, D., et al. (2020). Current progress, limitations, and future directions of real-time release testing for pharmaceutical tablets. *International Journal of Pharmaceutics, 582*: 119353.
20. Jiang, M., et al. (2017). Potential benefits and implementation challenges of real-time release testing in biopharmaceutical manufacturing. *Biotechnology and Bioengineering, 114*(11): 2445–2456.
21. Kim, E. J., et al. (2021). PAT-based tools for monitoring pharmaceutical unit operations and supporting continuous process verification strategies. *Pharmaceutics, 13*(6): 919.
22. Fischer, R.-P., Volpert, A., Antonino, P., & Ahrens, T. D. (2024). Digital patient twin technologies for individualized treatment and pharmaceutical production. *Frontiers in Digital Health, 5*: 1302338.